

## SUPPLEMENTARY MATERIAL

**Table S1.** Neutralizing titers (NT<sub>50</sub>) of BriLife® vaccinees against SARS-CoV-2 original virus, variants alpha, beta, and gamma (set 1). Samples that were below

<b>Vaccinee #</b>	<b>original virus</b>	<b>alpha</b>	<b>beta</b>	<b>gamma</b>
1	241	72	10	321
2	65	10	44	114
3	137	54	10	160
4	197	154	75	228
5	251	108	34	504
6	220	49	41	426
7	240	86	234	349
8	258	95	60	220
9	608	836	420	896
<b>Mean titer</b>	<b>246</b>	<b>163</b>	<b>103</b>	<b>357</b>
Fold change (relative to original virus)		1.5	2.4	0.7

LOD were assigned a value of 10 (half of the LOD).

**Table S2.** Neutralization titers (NT<sub>50</sub>) of BriLife® vaccinees against SARS-CoV-2 original virus, delta and omicron variant of concern (set 2). Samples that were below LOD were assigned a value of 10 (half of the LOD).


<b>Vaccinee #</b>	<b>original virus</b>	<b>delta</b>	<b>omicron</b>
1	121	85	85
2	130	66	48
3	42	149	55
4	166	85	47
5	208	210	175
6	112	80	68
7	133	104	75
8	83	10	38
9	375	383	25
10	94	10	43
11	141	172	10
12	295	273	10
13	80	78	10
<b>Mean titers</b>	<b>152</b>	<b>131</b>	<b>53</b>
Fold decrease (relative to original virus)		1.2	2.9

**Table S3.** Neutralization titers (NT<sub>50</sub>) of BriLife® vaccinees against rVSV-WT (Indiana serotype) at time zero (T0), 28 days post 1<sup>st</sup> vaccination (P) and two weeks following 2<sup>nd</sup> vaccination (P+B). Samples that were below LOD were assigned a value of 10 (half of the LOD).

<b>Vaccinee #</b>	<b>T0</b>	<b>P</b>	<b>P+B</b>
1	21	38	62
2	83	99	202
3	10	10	72
4	10	10	10
5	115	57	52
6	10	45	10
7	10	10	10
8	43	30	45
9	10	10	59
10	10	10	10
<b>Mean titers</b>	<b>32</b>	<b>32</b>	<b>53</b>

**Table S4.** Neutralizing titers (NT<sub>50</sub>) of convalescent sera against SARS-CoV-2 original virus, variants alpha, beta, gamma and delta (convalescent set). Samples that were below LOD were assigned a value of half of the LOD.

<b>Convalescent sera #</b>	<b>original virus</b>	<b>alpha</b>	<b>beta</b>	<b>gamma</b>	<b>delta</b>
1	541	296	279	423	85
2	1385	1027	760	953	212
3	758	197	139	333	160
4	142	177	160	95	79
5	366	100	107	297	178
6	323	40	79	269	115
7	119	41	65	132	39
8	104	20	66	40	103
9	123	51	39	50	41
<b>Mean titers</b>	<b>429</b>	<b>216</b>	<b>188</b>	<b>288</b>	<b>113</b>
Fold decrease (relative to original virus)		2.0	2.3	1.5	3.8



**Figure S1: Neutralization of alpha, beta, gamma and delta variants by sera from convalescent patients:** (a) NT<sub>50</sub> of convalescent patients' sera against SARS-CoV-2 original virus, in comparison to (a) alpha, (b) beta, (c) gamma and (d) delta (n=9) variants. Each serum is color coded for all tested viruses. LOD is indicated in each panel (a,c LOD=40; b,d LOD=20). Samples below LOD were assigned a value of half the LOD. Data is presented as mean ± SEM. Significance was determined by unpaired t-test. p values: 0.2454, 0.1514, 0.4184, 0.0409, for comparison of original virus to alpha, beta, gamma and delta, respectively.